Skip to main content
Journal of Orthopaedic Surgery and Research logoLink to Journal of Orthopaedic Surgery and Research
. 2022 Dec 24;17:564. doi: 10.1186/s13018-022-03458-x

Serum versus synovial fluid interleukin-6 for periprosthetic joint infection diagnosis: a systematic review and meta-analysis of 30 diagnostic test accuracy studies

Jian Li 1,#, Qian Zhou 2,#, Biquan Deng 1,
PMCID: PMC9789601  PMID: 36566223

Abstract

Background

Early and accurate detection of periprosthetic joint infection (PJI) after hip and/or knee arthroplasty remains challenging. This systematic review and meta-analysis of diagnostic test accuracy studies aimed to evaluate the diagnostic accuracy of serum and synovial fluid interleukin (IL)-6 in detecting PJI.

Methods

We searched 3 databases for studies through December 31, 2021, using medical sub-headings terms and keywords. Studies reported sensitivity and specificity of serum and synovial fluid IL-6 in detecting PJI were considered. We calculated the pooled sensitivity, specificity, positive and negative likelihood ratio, diagnostic odds ratio (DOR), and the area under the summary receiver operating characteristic curve (AUC) to evaluate the diagnostic accuracy of serum and synovial fluid IL-6.

Results

Thirty studies were included. The pooled sensitivity, specificity, positive and negative likelihood ratio, DOR, and AUC of serum IL-6 in detecting PJI were 0.76 (0.69–0.81), 0.88 (0.82–0.92), 6.2 (4.3–9.0), 0.28 (0.22–0.35), 22 (14–36), and 0.88 (0.85–0.91), respectively. However, synovial fluid IL-6 achieved a pooled sensitivity of 0.87 (0.75–0.93), specificity of 0.90 (0.85–0.93), positive and negative likelihood ratio of 8.5 (5.3–13.6) and 0.15 (0.08–0.29), DOR of 57 (21–156), and AUC of 0.94 (0.92–0.96), which were higher than serum IL-6.

Conclusions

Synovial fluid IL-6 test may be a promising test for PJI after hip and/or knee arthroplasty. However, considering the limited volume of synovial fluid and invasive acquisition of synovial fluid IL-6, serum IL-6 test may be also considered.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13018-022-03458-x.

Keywords: Knee, Hip, Arthroplasty, Interleukin-6, Diagnostic meta-analysis

Introduction

As a serious complication after knee and hip arthroplasties, periprosthetic joint infection (PJI) has been regarded as the main contributor to joint arthroplasty failure (20.4%) [1] and revision after joint arthroplasty [2]. Studies revealed that the number of patients who received arthroplasty resulted from PJI is five times more than patients who did not receive an arthroplasty for a PJI [3, 4]. PJI was also associated with an increased morbidity and mortality rate, and it therefore significantly increased the economic burden on the healthcare system [5, 6]. Early and accurate detection of PJI after knee and hip arthroplasty has become an important approach to minimize the risk caused by PJI. Unfortunately, it remains a challenge for early and accurately detecting PJI due to optimal diagnostic method is not available [7].

The current standard for the diagnosis of prosthetic joint infection is diagnostic criteria, and a series of tests have been offered to comprehensively detect PJI hip and/or knee arthroplasty [8]. It is noted that diagnostic tests based on biomarkers were found to have good diagnostic value in the early and accurate detection of PJI hip and/or knee arthroplasty in recent years, such as C-reactive protein (CRP) [9], α-defensin [10], leukocyte esterase [11], and interleukin-6 (IL-6) [12], and these biomarkers are a component of the diagnostic criteria. Nevertheless, meta-analysis indicated an inadequate overall diagnostic accuracy [13]. Among the existing biomarkers, the role of IL-6 in detecting PJI has been extensively investigated, and the clinical significance of IL-6 in distinguishing between infected and aseptic failed total joint replacements has also been suggested [14].

Currently, two meta-analyses [15, 16] have evaluated the diagnostic accuracy of IL-6 in detecting PJI and indicated the excellent diagnostic value of IL-6 in detecting PJI. However, different sources of IL-6 were speculated to be associated with different diagnostic accuracies; a previous meta-analysis was therefore conducted to determine the difference between serum and synovial fluid IL-6 in detecting PJI after hip, knee, and/or shoulder replacement. However, it is unclear whether these findings were suitable to patients only receiving hip and/or knee replacements. Moreover, numerous studies continued to focus attention on this issue after previous meta-analysis because a definitive conclusion as not yet been achieved for specific population. We therefore performed this systematic review and meta-analysis of diagnostic test accuracy (DTA) studies to further evaluate the diagnostic accuracy of serum and synovial fluid IL-6 in detecting of PJI after hip and/or knee arthroplasty through combining available studies.

Materials and methods

We performed this diagnostic meta-analysis according to the methods recommended by the Cochrane handbook [17] and reported it in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension for Diagnostic Test Accuracy (DTA) [18]. No ethical approval and patient’s informed consent was required because this is a meta-analysis of previously published studies. We did not register the formal protocol in any public platform.

Study retrieval

We systematically searched 3 databases including PubMed, EMBASE, and the Cochrane library for identifying relevant studies from their inception through to 31 December, 2021. Study search was performed by two qualified independent investigators (** and **). We used the following terms and its analogs to develop search query with Boolean operators: “periprosthetic joint infection”, “interleukin-6”, and “joint prosthesis”. The sensitivity of the search query was modified according to the unique requirements of each database. Additionally, we screened reference lists of eligible studies and published reviews to avoid missing relevant studies. No restriction on publication language and status was applied to literature retrieval. The third senior investigator (**) was consulted for resolving any disagreements during study retrieval. Details of the search query are summarized in Additional file 1: Table S1.

Selection criteria

We selected eligible studies according to the following criteria [16, 19]: (a) eligible patients were identified with PJI with recognized diagnostic criteria after hip and/or knee replacement; (b) serum or synovial fluid sample was obtained for diagnostic investigation in eligible studies; (c) studies reported the data of true positives (TP), false positives (FP), false negatives (FN), true negative (TN) or the sensitivity and specificity. We excluded ineligible studies according to the following criteria: (a) studies were performed to investigate the diagnostic value of IL-6 in detecting PJI after shoulder and/or elbow replacement; (b) ineligible study design such as narrative review, animal studies, or case report; (c) no control group was designed or direct comparison between samples were not available; (d) repeated reports focusing on the same topic published by the same group but with insufficient data and relatively poor quality; and (e) essential data were not accessible in original studies and additional data could not be added through contacting the leading author.

Study selection

Two independent qualified investigators selected eligible studies based on the selection criteria as follows: (a) all records identified from 3 electronic databases were imported into EndNote X9 to build literature database; (b) after removal of duplicate records, the titles and abstracts of retained records were screened; and (c) eligibility of the remaining studies was evaluated finally based on the screening for full-text. The third senior investigator was consulted for resolving any disagreements during study selection.

Data extraction

Two independent qualified investigators extracted the essential data from original studies, including the name of the first author, publication year, country, study design, the number of patients included for the final analysis, the number of PJI and aseptic cases, the diagnostic criteria of PJI, and the part of infected joint (knee, hip or mixed parts), cut-off value, and the diagnosis result including the numbers of TP, FP, FN, and TN, or sensitivity and specificity. We contacted the leading author to collect essential data if necessary. The third senior investigator was consulted for resolving any disagreement during data extraction.

Quality assessment

Two independent qualified investigators (** and **) evaluated the risk of bias and concerns about applicability of the included studies using the Quality Assessment for Studies of Diagnostic Accuracy Score (QUADAS) tool [20]. This tool determined the methodological quality of each study from four domains, including patient selection, index test, reference standard, and flow and timing. We assessed the risk of bias for all domains and applicability for the first three domains. We rated each domain as “low,” “unclear,” and “high” risk. The third senior investigator (**) was consulted for resolving any disagreement about quality assessment.

Statistical analysis

We firstly calculated the TP, FP, FN, and TN based on the available information extracted from the original studies, quantitative indicators with corresponding 95% confidence interval (CI) were then estimated for evaluating the diagnostic value of the serum and synovial fluid IL-6 for the detection of PJI after knee or hip arthroplasty, including the pooled sensitivity and specificity, the positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio (DOR), and the area under the summary receiver operating characteristic (SROC) curve (AUC) [21, 22]. Meanwhile, we evaluated statistical heterogeneity across studies based on the χ2 test and I2 statistics, and I2 ≥ 50% suggested the presence of substantial heterogeneity [23]. Nevertheless, we used the random-effects model to perform data synthesis because variations between studies should not be ignored in real settings. Additionally, we performed the subgroup analysis to furtherly investigate the influence of various characteristics on the diagnostic accuracy of serum and synovial fluid IL-6 test for the diagnosis of PJI. Finally, we created the Deek’s funnel plot to evaluate the risk of publication bias [24]. Data analysis was performed by using STATA 14.0 (StataCorp, College Station, TX, USA) with the “midas” module.

Results

Literature retrieval

We identified 515 records from 3 databases. A total of 133 duplicate records were removed using EndNote software. We excluded 332 ineligible studies after screening the titles and abstracts. Among 50 studies retained for further eligibility evaluation, 20 studies were excluded due to ineligible participants (n = 7), ineligible study design (n = 3), insufficient data (n = 5), and ineligible test (n = 5). Finally, 30 studies[12, 14, 2545] were judged for meeting selection criteria, including 23 reports for serum IL-6 and 14 reports for synovial fluid IL-6. The flow diagram of the study selection is displayed in Fig. 1.

Fig. 1.

Fig. 1

The PRISMA flowchart of study selection

Basic characteristics of eligible studies

We designed Table 1 to summarize the basic characteristics of 30 eligible studies. Totally, 3218 patients were accumulated, involving 1223 patients with PJI and 1995 patients with aseptic loosing. All studies were published between 2005 and 2021. Among the included studies, 9 studies [12, 29, 4450] performed in China, 7 studies [27, 3032, 36, 51] in USA, 5 studies [14, 26, 35, 37, 39] in Germany, 2 studies [25, 33] in Egypt, 2 studies [38, 41] in Austria, and remaining studies in Argentina [28], Poland [40], Turkey [34], UK [52], Slovenia [42], and Sweden [43], respectively. Four studies [12, 28, 43, 52] enrolled patients receiving hip replacement, but remaining studies [14, 2527, 2942, 4449, 51, 52] included patients undergoing both hip and knee replacements. Twenty studies [12, 14, 25, 26, 29, 31, 3438, 41, 4451] clearly reported to use the Musculoskeletal Infection Society criteria (MSIS) criteria for the diagnosis of PJI. The methodological quality of included studies was moderate, which is shown in Fig. 2.

Table 1.

Basic characteristics of 30 studies included in this diagnostic meta-analysis

Study Country Design Sample (PJI/Aseptic) Male/Female Mean age, years (PJI vs Aseptic) Affected part Exclusion of inflammatory diseases Diagnosis of PJI Cut-off, pg/mL Type of PJI
serum IL-6
Abou, et al., [25] Egypt PS 40 (11/29) 21/19 58.4 Mixed Yes MSIS 10.4 No clear information
Ackmann, et al., [26] Germany RS 119 (52/67) 69/50 70.5 vs 68 Mixed Yes MSIS 10.0 Chronic PJI
Buttaro, et al., [28] Argentina PS 69 (11/58) 50/19 68 Hip Yes Other 10.0 No clear information
Di, et al., [32] USA PS 58 (17/41) 25/33 63 Mixed Yes Other 10.0 Chronic PJI
Glehr, et al., [38] Austria PS 84 (55/29) 38/46 NA Mixed Yes MSIS 4.7 No clear information
Yu, et al., [49] China RS 121 (20/101) 35/86 68.2 vs 64.9 Mixed Yes MSIS 8.1 Acute PJI
Yu, et al., [50] China RS 139 (62/77) 46/93 65.85 vs 64.60 Mixed No MSIS 8.980 No clear information
Chu, et al., [29] China RS 35 (16/19) 14/21 66 vs 65 Mixed NA MSIS NA No clear information
Klim, et al., [41] Austria PS 84 (55/29) 38/46 65.7 vs 65.1 Mixed Yes MSIS 5.7 No clear information
Grzelecki, et al., [40] Poland PS 85 (45/40) 25/60 65.5 vs 68.3 Mixed Yes Other 7 Chronic PJI
Xu, et al., 2019 China RS 318 (129/189) NA NA Mixed Yes MSIS 8.57 No clear information
Yin, et al., [48] China NA 35 (15/20) 21/14 66.4 vs 68.7 Mixed NA MSIS 23.05 No clear information
Erdemli, et al., [34] Turkey PS 88 (36/25) 27/61 68.7 Mixed No MSIS 16.2 No clear information
Tang, et al., [46] China RS 52 (21/31) 22/30 65.5 vs 61.7 Mixed No MSIS 7.5 No clear information
Worthington, et al., [52] UK PS 46 (16/30) 25/21 72 Hip Yes NA 9 No clear information
Bottner, et al., [27] USA PS 78 (21/57) 41/37 63.5 vs 64.8 Mixed No Other 12.0 No clear information
Elgeidi, et al., [33] Egypt PS 40 (11/29) 21/19 59.6 vs 57.9 Mixed Yes Other 10.4 No clear information
Qu, et al., [12] China RS 86 (16/70) 48/38 56 vs 54 Hip No MSIS 8.12 No clear information
Qin, et al., [44] China PS 93 (37/56) 58/35 74.57 vs 72.15 Mixed Yes MSIS 6.7 No clear information
Qin, et al., [45] China PS 70 (35/35) 35/35 63.66 vs 66.2 Mixed Yes MSIS 6.1 No clear information
Gollwitzer, et al., [39] Germany PS 35 (15/20) 12/23 71 vs 70 Mixed Yes Other 1.89 Chronic PJI
Randau, et al., [14] Germany PS 120 (48/72) 47/73 NA Mixed NA MSIS 2.6 No clear information
Randau, et al., [14] Germany PS 120 (48/72) 47/73 NA Mixed NA MSIS 6.6 No clear information
synovial IL-6
Sharma, et al., [51] USA NA 107 (50/57) 57/50 65.6 vs 66.2 Mixed NA MSIS NA Acute, chronic, and hematogenous PJI
Fröschen, et al., [37] Germany RS 32 (14/18) 11/21 73.8 vs 62.28 Mixed No MSIS 1975 No clear information
Ettinger, et al., [35] Germany PS 72 (12/60) NA NA Mixed No MSIS 373 Chronic PJI
Mihalič, et al., [42] Slovenia PS 48 (11/37) 23/25 68 Mixed No Other 2300 Acute and chronic PJI
Frangiamore, et al., [36] USA PS 90 (31/59) 39/51 63 vs 65 Mixed No MSIS 8671.0 No clear information
Deirmengian, et al., [31] USA PS 95 (29/66) 44/51 67 vs 66 Mixed No MSIS 2300 No clear information
Nilsdotter-Augustinsson, et al., [43] Sweden PS 131 (25/106) 64/67 NA Hip No Other 10,000 No clear information
Deirmengian, et al., [30] USA PS 51 (14/37) 23/28 65 Mixed No Other 13,350 No clear information
Yu, et al., [50] China RS 139 (62/77) 46/93 65.85 vs 64.60 Mixed No MSIS 6590.289 No clear information
Qin, et al., [44] China PS 93 (37/56) 58/35 74.57 vs 72.15 Mixed Yes MSIS 1855.36 Chronic PJI
Qin, et al., [45] China PS 70 (35/35) 35/35 63.66 vs 66.2 Mixed Yes MSIS 1950 Chronic PJI
Gollwitzer, et al., [39] Germany PS 35 (15/20) 12/23 71 vs 70 Mixed Yes Other 1896.56 No clear information
Randau, et al., [14] Germany PS 120 (48/72) 47/73 NA Mixed No MSIS 2100 No clear information
Randau, et al., [14] Germany PS 120 (48/72) 47/73 NA Mixed No MSIS 9000 No clear information

PJI Periprosthetic joint infection, IL-6 Interleukin-6, PS Prospective study, RS Retrospective study, MSIS Musculoskeletal Infection Society criteria, NA Not available

Fig. 2.

Fig. 2

Quality assessment of the included studies

Diagnostic accuracy of serum and synovial fluid IL-6

A total of 23 reports evaluated the diagnostic accuracy of serum IL-6 for detecting PJI after hip and/or knee replacement, and meta-analysis suggested that, as shown in Fig. 3a, the pooled sensitivity and specificity was 0.76 (95%CI 0.69–0.81) and 0.88 (95%CI 0.82–0.92), respectively. Meanwhile, serum IL-6 reached a relatively high diagnostic accuracy, with an AUC of 0.88 (95%CI 0.85–0.91), which is shown in Fig. 4a. For the evaluation of diagnostic accuracy of synovial fluid IL-6, 14 reports were provided for data analysis. Meta-analysis suggested that, as shown in Fig. 3b, the pooled sensitivity and specificity were 0.87 (95%CI 0.75–0.93) and 0.90 (95%CI 0.85–0.93), respectively. Additionally, serum IL-6 received a higher diagnostic accuracy, with an AUC of 0.94 (95%CI 0.92–0.96) (Fig. 4b). This indicated that the diagnostic performance of synovial fluid IL-6 for PJI was superior to serum IL-6.

Fig. 3.

Fig. 3

Forest plot of the pooled sensitivity and specificity of serum IL-6 a and synovial fluid IL-6 b for diagnosis of periprosthetic joint infection

Fig. 4.

Fig. 4

SROC curve of serum IL-6 a and synovial fluid IL-6 b for diagnosis of periprosthetic joint infection

Evaluation of the clinical utility

Meta-analysis suggested that, as shown in Fig. 5, serum IL-6 achieved a positive likelihood ratio of 6.2 (95%CI 4.3–9.0) and a negative likelihood ratio of 0.28 (95%CI 0.22–0.35) for detecting PJI; however, synovial fluid IL-6 achieved a positive likelihood ratio of 8.5 (95%CI 5.3–13.6) and a negative likelihood ratio of 0.15 (95%CI 0.08–0.29). Moreover, the DOR of serum and synovial fluid IL-6 was 22 (95%CI 14–36) and 57 (95%CI 21–156), respectively. We designed 50% pre-test probabilities to estimate the post-test probability in this study, and a post-test probability of 22% was achieved for PJI in serum IL-6 test and 13% in synovial IL-6 test. This suggested synovial IL-6 test was linked to higher clinical utility compared to serum IL-6 test.

Fig. 5.

Fig. 5

Fagan's nomogram of the post-test probability of IL-6 for diagnosis of periprosthetic joint infection based on the pre-test probability of 50% in serum IL-6 a and synovial fluid IL-6 b

Subgroup analysis

Substantial heterogeneity was observed for both serum and synovial fluid IL-6 tests. Subgroup analyses were therefore performed to check the robustness of pooled results based on pre-designed criteria, including exclusion of chronic inflammatory diseases or not, the part of affected joints (mixed joint replacements or hip replacement), the diagnostic criteria for PJI (MSIS criteria or others), study design (prospective or retrospective), the number of patients included for analysis (60 for serum IL-6 and 80 for synovial fluid IL-6), and the cut-off criteria (10 pg/ml for serum IL-6 and 2300 pg/ml for synovial fluid IL-6). As shown in Additional file 2: Table S2, subgroup analysis confirmed the robustness of pooled results. However, it is noted that the number of patients included for analysis and the cut-off criteria for PJI might have an impact on the diagnostic accuracy.

Publication bias

Deek’s funnel plot suggested that the studies were symmetrically located on both sides of the regression line. Furthermore, the asymmetric test for Deek’s plot quantitatively disclosed absence of publication bias for both serum and synovial fluid IL-6, with a P value of 0.27 and 0.61, respectively (Fig. 6).

Fig. 6.

Fig. 6

Deek's funnel plot of serum IL-6 a and synovial fluid IL-6 b

Discussion

Although IL-6 has been suggested to have relatively high diagnostic value in detecting PJI, and difference between serum and synovial fluid IL-6 tests in detecting PJI after hip, knee and shoulder replacements has also been initially evaluated, there was no systematic review and meta-analysis to evaluate the diagnostic accuracy of serum and synovial fluid IL-6 tests in detecting PJI among patients who underwent only hip and knee replacements. In this systematic review and meta-analysis of 30 DTA studies, we evaluated the diagnostic value of both serum and synovial fluid IL-6 tests for detecting PJI after hip and knee replacements, and found that synovial fluid IL-6 might be preferentially prescribed for detecting PJI after hip and knee replacements owing to its higher sensitivity, specificity, DOR, and diagnostic accuracy. Certainly, serum IL-6 might also be considered for detecting PJI after hip and knee owing to its comparable specificity to synovial fluid IL-6 because the volume of synovial fluid is limited and the acquisition of synovial fluid IL-6 is invasive. Moreover, more studies are required to further determine the optimal cut-off value of both serum and synovial fluid IL-6 tests because a negative association between diagnostic accuracy of IL-6 and cut-off criteria has been revealed.

Up to now, numerous systematic reviews and meta-analyses of DTA studies evaluated the diagnostic value of IL-6 in detecting PJI; however, a definitive conclusion has not yet been achieved due to several limitations, which were further explained in the following contents. In 2017, Lee et al. [13] found that synovial fluid IL-6 test was associated with higher diagnostic accuracy, indicating an AUC, sensitivity and specificity of 0.95, 0.81 and 0.94, respectively. In the same year, another meta-analysis reported a similar diagnostic accuracy, with an AUC of 0.956 [53]. It is noted that these findings were calculated from 5 [13] or 7 [53] eligible studies although they achieved consistent diagnostic accuracy with our meta-analysis; however, 14 reports were included in this study to generate more robust and reliable results. In 2020, a meta-analysis by Li et al. [54] found that serum IL-6 achieved a pooled sensitivity, specificity and DOR of 0.87, 0.83, and 36.27, respectively, as well as an AUC of 0.92. Insufficient eligible studies impaired the reliability of pooled results although a higher diagnostic accuracy was achieved compared with our study, in which 23 eligible reports were included for the estimation of diagnostic accuracy.

In 2017, Xie et al. performed a systematic review and meta-analysis of 17 DTA studies to investigate the relative diagnostic values of serum and synovial fluid IL-6 tests for PJI after hip, knee and shoulder replacements [19], suggesting that synovial fluid IL-6 test had a higher AUC (0.96 vs. 0.83) and DOR (101 vs. 20) as well as comparable specificity (0.90 vs. 0.89) relative to serum IL-6 test. Based on these results, authors concluded that serum IL-6 may be regularly prescribed for detecting PJI owing to its relatively high specificity although it had less sensitive than synovial fluid IL-6 test. Yoon et al. [15] included 16 eligible DTA studies for data analysis and found that IL-6 achieved an AUC of 0.93 in detecting PJI after hip, knee, shoulder, and/or elbow replacement, with a pooled sensitivity and specificity of 0.83 and 0.91, respectively. Meanwhile, Tian et al. performed a diagnostic meta-analysis, and pooled results suggested a higher diagnostic accuracy (0.91), corresponding to a sensitivity of 0.80 and a pooled specificity of 0.89 [16].

Compared with previous systematic reviews and meta-analyses of DTA studies, our study minimizes the variation in patient’s characteristics because only patients receiving hip and/or knee replacement were considered. Moreover, this was the first meta-analysis to determine the diagnostic value of serum and synovial fluid IL-6 in detecting PJI after hip and/or knee replacement through combining the greatest number of eligible studies. As an example, our study confirmed that synovial fluid IL-6 test was associated with higher DOR compared with serum IL-6 test, which was directionally consistent with previous meta-analysis. Specificity speaking, a pooled DOR of 57 with a corresponding 95%CI of 21 to 156 was generated in our study, while previous systematic reviews and meta-analyses of DTA studies reported a pooled DOR of 101, with a 95%CI of 28 to 358.

Our systematic review and meta-analysis of 30 DTA studies had some limitations. First, although we selected a random-effects model to calculate results, it is still a fact that substantial heterogeneity was present for both serum and synovial fluid IL-6 tests, which might lower the reliability of our findings. However, we believed that all findings from the present study could be preferentially considered in clinical practice because subgroup analysis confirmed the robustness of our results. Second the formal protocol of this systematic review and meta-analysis of DTA studies was not registered in any platform. However, we strictly performed data analysis and reported pooled results according to the recommended criteria, which greatly enhance the strictness and reliability of this study. Third, we included the greatest number of eligible studies to update the diagnostic accuracy of serum and synovial fluid IL-6 based on a systematic literature retrieval; however, the risk of missing eligible studies could not be avoided because other databases such as Web of Science and China National Knowledge Infrastructure (CNKI) were not retrieved. Fourth, we performed a series of subgroup analyses to investigate the contribution of some important factors to statistical heterogeneity; however, statistical heterogeneity was not significantly reduced after these subgroup analyses. Therefore, our findings should be interpreted with caution, as further analysis cannot be performed based on other potential factors. Finally, it must be acknowledged that distinguishing the diagnostic values of serum or synovial IL-6 for different types of PJI is important because chronicity of the PJI makes a different diagnosis criterion. However, most of the eligible studies did not provide details on PJI type, so further analysis by PJI type was not possible.

Conclusion

Synovial fluid IL-6 test has significantly higher diagnostic accuracy for the detection of PJI among patients undergoing hip and/or knee replacement. Although serum IL-6 test is less sensitive than synovial fluid IL-6 test, it can also be considered for patients with prosthetic failure due to its comparable specificity to synovial fluid IL-6 test. Certainly, our findings should be interpreted with caution due to significant statistical heterogeneity. Moreover, more studies should be performed to determine the optimal cut-off value because it has a negative impact on the diagnostic accuracy of IL-6 in patients undergoing hip and/or knee replacement.

Supplementary Information

13018_2022_3458_MOESM1_ESM.docx (23.3KB, docx)

Additional file 1: Table S1. Search query of electronic databases.

13018_2022_3458_MOESM2_ESM.docx (24.4KB, docx)

Additional file 2: Table S2. Analysis of the subgroup.

Acknowledgements

We would like to deeply appreciate all authors who performed all eligible studies which have been included in the present network meta-analysis.

Author contributions

Conception and design: J L. Administrative support: BQ D. Provision of study materials or patients: Q Z. Collection and assembly of data: Q Z. Data analysis and interpretation: J L & BQ D. Manuscript writing: All authors. Final approval of manuscript: All authors.

Funding

This work was supported by the Scientific Research Project of Wuhan Municipal Health Commission (NO. WX16C49).

Availability of data and materials

All data generated or analyzed during this study are included in this published article/as Additional files.

Declarations

Ethics approval and consent to participate

Not Applicable.

Consent for publication

Not Applicable.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jian Li and Qian Zhou authors are co-first authors.

References

  • 1.Delanois RE, Mistry JB, Gwam CU, Mohamed NS, Choksi US, Mont MA. Current epidemiology of revision total knee arthroplasty in the United States. J Arthroplasty. 2017;32(9):2663–2668. doi: 10.1016/j.arth.2017.03.066. [DOI] [PubMed] [Google Scholar]
  • 2.Gwam CU, Mistry JB, Mohamed NS, Thomas M, Bigart KC, Mont MA, et al. Current epidemiology of revision total hip arthroplasty in the United States: national inpatient sample 2009 to 2013. J Arthroplasty. 2017;32(7):2088–2092. doi: 10.1016/j.arth.2017.02.046. [DOI] [PubMed] [Google Scholar]
  • 3.Goswami K, Parvizi J, Maxwell CP. Current recommendations for the diagnosis of acute and chronic PJI for hip and knee-cell counts, alpha-defensin, leukocyte esterase. Next-Generation Sequencing Curr Rev Musculoskelet Med. 2018;11(3):428–438. doi: 10.1007/s12178-018-9513-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Zmistowski B, Karam JA, Durinka JB, Casper DS, Parvizi J. Periprosthetic joint infection increases the risk of one-year mortality. J Bone Joint Surg Am. 2013;95(24):2177–2184. doi: 10.2106/JBJS.L.00789. [DOI] [PubMed] [Google Scholar]
  • 5.Poultsides LA, Liaropoulos LL, Malizos KN. The socioeconomic impact of musculoskeletal infections. J Bone Joint Surg Am. 2010;92(11):e13. doi: 10.2106/JBJS.I.01131. [DOI] [PubMed] [Google Scholar]
  • 6.Boddapati V, Fu MC, Mayman DJ, Su EP, Sculco PK, McLawhorn AS. Revision total knee arthroplasty for periprosthetic joint infection is associated with increased postoperative morbidity and mortality relative to noninfectious revisions. J Arthroplasty. 2018;33(2):521–526. doi: 10.1016/j.arth.2017.09.021. [DOI] [PubMed] [Google Scholar]
  • 7.Bauer TW, Parvizi J, Kobayashi N, Krebs V. Diagnosis of periprosthetic infection. J Bone Joint Surg Am. 2006;88(4):869–882. doi: 10.2106/JBJS.E.01149. [DOI] [PubMed] [Google Scholar]
  • 8.Shohat N, Bauer T, Buttaro M, Budhiparama N, Cashman J, Della Valle CJ, et al. Hip and Knee Section, What is the definition of a periprosthetic joint infection (PJI) of the knee and the hip? Can the same criteria be used for both joints?: Proceedings of international consensus on orthopedic infections. J Arthroplasty. 2019;34(2s):S325-s7. [DOI] [PubMed]
  • 9.Unter Ecker N, Suero EM, Gehrke T, Haasper C, Zahar A, Lausmann C, et al. Serum C-reactive protein relationship in high- versus low-virulence pathogens in the diagnosis of periprosthetic joint infection. J Med Microbiol. 2019;68(6):910–917. doi: 10.1099/jmm.0.000958. [DOI] [PubMed] [Google Scholar]
  • 10.Bonanzinga T, Zahar A, Dütsch M, Lausmann C, Kendoff D, Gehrke T. How reliable is the alpha-defensin immunoassay test for diagnosing periprosthetic joint infection? A prospective study. Clin Orthop Relat Res. 2017;475(2):408–415. doi: 10.1007/s11999-016-4906-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Shahi A, Alvand A, Ghanem E, Restrepo C, Parvizi J. The Leukocyte esterase test for periprosthetic joint infection is not affected by prior antibiotic administration. J Bone Joint Surg Am. 2019;101(8):739–744. doi: 10.2106/JBJS.18.00615. [DOI] [PubMed] [Google Scholar]
  • 12.Qu PF, Xu C, Fu J, Li R, Chai W, Chen JY. Does serum interleukin-6 guide the diagnosis of persistent infection in two-stage hip revision for periprosthetic joint infection? J Orthop Surg Res. 2019;14(1):354. doi: 10.1186/s13018-019-1448-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Lee YS, Koo KH, Kim HJ, Tian S, Kim TY, Maltenfort MG, et al. Synovial fluid biomarkers for the diagnosis of periprosthetic joint infection: a systematic review and meta-analysis. J Bone Joint Surg Am. 2017;99(24):2077–2084. doi: 10.2106/JBJS.17.00123. [DOI] [PubMed] [Google Scholar]
  • 14.Randau TM, Friedrich MJ, Wimmer MD, Reichert B, Kuberra D, Stoffel-Wagner B, et al. Interleukin-6 in serum and in synovial fluid enhances the differentiation between periprosthetic joint infection and aseptic loosening. PLoS ONE. 2014;9(2):e89045. doi: 10.1371/journal.pone.0089045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yoon JR, Yang SH, Shin YS. Diagnostic accuracy of interleukin-6 and procalcitonin in patients with periprosthetic joint infection: a systematic review and meta-analysis. Int Orthop. 2018;42(6):1213–1226. doi: 10.1007/s00264-017-3744-3. [DOI] [PubMed] [Google Scholar]
  • 16.Tian B, Cui L, Jiang W. The diagnostic effect of α-defensin, D-dimer, and IL-6 in periprosthetic joint infection: a systematic review and diagnostic meta-analysis. J Orthop Surg (Hong Kong) 2020;28(3):2309499020971861. doi: 10.1177/2309499020971861. [DOI] [PubMed] [Google Scholar]
  • 17.Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook.
  • 18.McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA. 2018;319(4):388–396. doi: 10.1001/jama.2017.19163. [DOI] [PubMed] [Google Scholar]
  • 19.Xie K, Dai K, Qu X, Yan M. Serum and synovial fluid interleukin-6 for the diagnosis of periprosthetic joint infection. Sci Rep. 2017;7(1):1496. doi: 10.1038/s41598-017-01713-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–536. doi: 10.7326/0003-4819-155-8-201110180-00009. [DOI] [PubMed] [Google Scholar]
  • 21.Devillé WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol. 2002;2:9. doi: 10.1186/1471-2288-2-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12(14):1293–1316. doi: 10.1002/sim.4780121403. [DOI] [PubMed] [Google Scholar]
  • 23.Gardiner JC, Luo Z, Roman LA. Fixed effects, random effects and GEE: what are the differences? Stat Med. 2009;28(2):221–239. doi: 10.1002/sim.3478. [DOI] [PubMed] [Google Scholar]
  • 24.Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005;58(9):882–893. doi: 10.1016/j.jclinepi.2005.01.016. [DOI] [PubMed] [Google Scholar]
  • 25.Abou El-Khier NT, El Ganainy AR, Elgeidy A, Rakha SA. Assessment of interleukin-6 and other inflammatory markers in the diagnosis of Egyptian patients with periprosthetic joint infection. Egypt J Immunol. 2013;20(2):93–99. [PubMed] [Google Scholar]
  • 26.Ackmann T, Möllenbeck B, Gosheger G, Schwarze J, Schmidt-Braekling T, Schneider KN, et al. Comparing the diagnostic value of serum D-dimer to CRP and IL-6 in the diagnosis of chronic prosthetic joint infection. J Clin Med. 2020;9(9):2917. doi: 10.3390/jcm9092917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Bottner F, Wegner A, Winkelmann W, Becker K, Erren M, Götze C. Interleukin-6, procalcitonin and TNF-alpha: markers of peri-prosthetic infection following total joint replacement. J Bone Joint Surg Br. 2007;89(1):94–99. doi: 10.1302/0301-620X.89B1.17485. [DOI] [PubMed] [Google Scholar]
  • 28.Buttaro MA, Tanoira I, Comba F, Piccaluga F. Combining C-reactive protein and interleukin-6 may be useful to detect periprosthetic hip infection. Clin Orthop Relat Res. 2010;468(12):3263–3267. doi: 10.1007/s11999-010-1451-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Chu L, Ren YL, Yang JS, Yang J, Zhou H, Jiang HT, et al. The combinations of multiple factors to improve the diagnostic sensitivity and specificity after artificial joint infection. J Orthop Surg Res. 2020;15(1):161. doi: 10.1186/s13018-020-01669-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Deirmengian C, Hallab N, Tarabishy A, Della Valle C, Jacobs JJ, Lonner J, et al. Synovial fluid biomarkers for periprosthetic infection. Clin Orthop Relat Res. 2010;468(8):2017–2023. doi: 10.1007/s11999-010-1298-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Deirmengian C, Kardos K, Kilmartin P, Cameron A, Schiller K, Parvizi J. Diagnosing periprosthetic joint infection: has the era of the biomarker arrived? Clin Orthop Relat Res. 2014;472(11):3254–3262. doi: 10.1007/s11999-014-3543-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Di Cesare PE, Chang E, Preston CF, Liu CJ. Serum interleukin-6 as a marker of periprosthetic infection following total hip and knee arthroplasty. J Bone Joint Surg Am. 2005;87(9):1921–1927. doi: 10.2106/00004623-200509000-00003. [DOI] [PubMed] [Google Scholar]
  • 33.Elgeidi A, Elganainy AE, Abou Elkhier N, Rakha S. Interleukin-6 and other inflammatory markers in diagnosis of periprosthetic joint infection. Int Orthop. 2014;38(12):2591–2595. doi: 10.1007/s00264-014-2475-y. [DOI] [PubMed] [Google Scholar]
  • 34.Erdemli B, Özbek EA, Başarir K, Karahan ZC, Öcal D, Biriken D. Proinflammatory biomarkers' level and functional genetic polymorphisms in periprosthetic joint infection. Acta Orthop Traumatol Turc. 2018;52(2):143–147. doi: 10.1016/j.aott.2017.11.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Ettinger M, Savov P, Calliess T, Windhagen H, Lichtinghagen R, Lukasz A, et al. Improved diagnostic accuracy with the classification tree method for diagnosing low-grade periprosthetic joint infections by quantitative measurement of synovial fluid alpha-defensin and C-reactive protein. Int Orthop. 2020;44(1):31–38. doi: 10.1007/s00264-019-04338-6. [DOI] [PubMed] [Google Scholar]
  • 36.Frangiamore SJ, Siqueira MB, Saleh A, Daly T, Higuera CA, Barsoum WK. Synovial cytokines and the MSIS criteria are not useful for determining infection resolution after periprosthetic joint infection explantation. Clin Orthop Relat Res. 2016;474(7):1630–1639. doi: 10.1007/s11999-016-4710-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Fröschen FS, Schell S, Schildberg FA, Klausing A, Kohlhof H, Gravius S, et al. Analysis of synovial biomarkers with a multiplex protein microarray in patients with PJI undergoing revision arthroplasty of the hip or knee joint. Arch Orthop Trauma Surg. 2020;140(12):1883–1890. doi: 10.1007/s00402-020-03388-5. [DOI] [PubMed] [Google Scholar]
  • 38.Glehr M, Friesenbichler J, Hofmann G, Bernhardt GA, Zacherl M, Avian A, et al. Novel biomarkers to detect infection in revision hip and knee arthroplasties infection. Clin Orthop Relat Res. 2013;471(8):2621–2628. doi: 10.1007/s11999-013-2998-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gollwitzer H, Dombrowski Y, Prodinger PM, Peric M, Summer B, Hapfelmeier A, et al. Antimicrobial peptides and proinflammatory cytokines in periprosthetic joint infection. J Bone Joint Surg Am. 2013;95(7):644–651. doi: 10.2106/JBJS.L.00205. [DOI] [PubMed] [Google Scholar]
  • 40.Grzelecki D, Walczak P, Szostek M, Grajek A, Rak S, Kowalczewski J. Blood and synovial fluid calprotectin as biomarkers to diagnose chronic hip and knee periprosthetic joint infections. Bone Joint J. 2021;103(1):46–55. doi: 10.1302/0301-620X.103B1.BJJ-2020-0953.R1. [DOI] [PubMed] [Google Scholar]
  • 41.Klim SM, Amerstorfer F, Glehr G, Hauer G, Smolle MA, Leitner L, et al. Combined serum biomarker analysis shows no benefit in the diagnosis of periprosthetic joint infection. Int Orthop. 2020;44(12):2515–2520. doi: 10.1007/s00264-020-04731-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Mihalič R, Zdovc J, Brumat P, Trebše R. Synovial fluid interleukin-6 is not superior to cell count and differential in the detection of periprosthetic joint infection. Bone Jt Open. 2020;1(12):737–742. doi: 10.1302/2633-1462.112.BJO-2020-0166.R1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Nilsdotter-Augustinsson A, Briheim G, Herder A, Ljunghusen O, Wahlström O, Ohman L. Inflammatory response in 85 patients with loosened hip prostheses: a prospective study comparing inflammatory markers in patients with aseptic and septic prosthetic loosening. Acta Orthop. 2007;78(5):629–639. doi: 10.1080/17453670710014329. [DOI] [PubMed] [Google Scholar]
  • 44.Qin L, Li X, Wang J, Gong X, Hu N, Huang W. Improved diagnosis of chronic hip and knee prosthetic joint infection using combined serum and synovial IL-6 tests. Bone Joint Res. 2020;9(9):587–592. doi: 10.1302/2046-3758.99.BJR-2020-0095.R1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Qin L, Wang H, Zhao C, Chen C, Chen H, Li X, et al. Serum and synovial biomarkers for distinguishing between chronic periprosthetic joint infections and rheumatoid arthritis: a prospective cohort study. J Arthroplasty. 2022;37(2):342–346. doi: 10.1016/j.arth.2021.09.009. [DOI] [PubMed] [Google Scholar]
  • 46.Tang X, Wang Q, Wang H, Wang S, Zhong Q, Li Z, et al. Comparison and estimation of different diagnostic methods in detecting the presence of periprosthetic joint infection. Zhonghua Wai Ke Za Zhi. 2016;54(4):251–257. doi: 10.3760/cma.j.issn.0529-5815.2016.04.003. [DOI] [PubMed] [Google Scholar]
  • 47.Xu H, Xie J, Huang Q, Lei Y, Zhang S, Pei F. Plasma fibrin degradation product and D-dimer are of limited value for diagnosing periprosthetic joint infection. J Arthroplasty. 2019;34(10):2454–2460. doi: 10.1016/j.arth.2019.05.009. [DOI] [PubMed] [Google Scholar]
  • 48.Yin H, Xu D, Wang D. Diagnostic value of next-generation sequencing to detect periprosthetic joint infection. BMC Musculoskelet Disord. 2021;22(1):252. doi: 10.1186/s12891-021-04116-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yu BZ, Fu J, Chai W, Hao LB, Chen JY. Neutrophil to lymphocyte ratio as a predictor for diagnosis of early Periprosthetic joint infection. BMC Musculoskelet Disord. 2020;21(1):706. doi: 10.1186/s12891-020-03704-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yu BZ, Li R, Li X, Chai W, Zhou YG, Chen JY. The relationship of C-reactive protein/interleukin-6 concentrations between serum and synovial fluid in the diagnosis of periprosthetic joint infection. J Orthop Surg Res. 2021;16(1):733. doi: 10.1186/s13018-021-02880-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Sharma K, Ivy M, Block DR, Abdel MP, Hanssen AD, Beauchamp C, et al. Comparative analysis of 23 synovial fluid biomarkers for hip and knee periprosthetic joint infection detection. J Orthop Res. 2020;38(12):2664–2674. doi: 10.1002/jor.24766. [DOI] [PubMed] [Google Scholar]
  • 52.Worthington T, Dunlop D, Casey A, Lambert R, Luscombe J, Elliott T. Serum procalcitonin, interleukin-6, soluble intercellular adhesin molecule-1 and IgG to short-chain exocellular lipoteichoic acid as predictors of infection in total joint prosthesis revision. Br J Biomed Sci. 2010;67(2):71–76. doi: 10.1080/09674845.2010.11730294. [DOI] [PubMed] [Google Scholar]
  • 53.Saleh A, Ramanathan D, Siqueira MBP, Klika AK, Barsoum WK, Rueda CAH. The diagnostic utility of synovial fluid markers in periprosthetic joint infection: a systematic review and meta-analysis. J Am Acad Orthop Surg. 2017;25(11):763–772. doi: 10.5435/JAAOS-D-16-00548. [DOI] [PubMed] [Google Scholar]
  • 54.Li C, Ojeda Thies C, Xu C, Trampuz A. Is combining serum interleukin-6 and C-reactive protein a reliable diagnostic tool in periprosthetic joint infections? J Orthop Surg Res. 2020;15(1):450. doi: 10.1186/s13018-020-01864-7. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

13018_2022_3458_MOESM1_ESM.docx (23.3KB, docx)

Additional file 1: Table S1. Search query of electronic databases.

13018_2022_3458_MOESM2_ESM.docx (24.4KB, docx)

Additional file 2: Table S2. Analysis of the subgroup.

Data Availability Statement

All data generated or analyzed during this study are included in this published article/as Additional files.


Articles from Journal of Orthopaedic Surgery and Research are provided here courtesy of BMC

RESOURCES